Beaver Run Resort Floorplan

Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
- Meeting Program
- Meeting Summary
- Abstract Information
- Registration Information
- Scholarships / Awards
- Lodging / Hotels
- Travel / Transportation
- Conference Location
- Things to Do
- Services
- My Account
This meeting will be conducted in English.
All programs are subject to change. Check this site for updates.

Twitter hashtag for this meeting: #KSantibodies
Antibodies as Drugs: New Horizons in the Therapeutic Use of Engineered Antibodies (D2)
Scientific Organizers: Christian Klein, Mark S. Cragg and Germaine Fuh
April 7—11, 2019
Beaver Run Resort, Breckenridge, Colorado, USA
Sponsored by AbbVie Inc., Bioverativ Therapeutics, ImmunoGen, Inc., Incyte Corporation, Merck & Co., Inc., MorphoSys AG, Roche and Valerion Therapeutics
IT’S NOT TOO LATE TO SUBMIT YOUR ABSTRACT. Abstracts received can no longer be considered for oral short talks. Abstracts for poster display opportunities will be accepted until 6 weeks before meeting start date midnight MST.
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies.
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Deadline: Dec 11, 2018 [details]
Discounted Abstract Deadline: Dec 11, 2018 [details]
Abstract Deadline: Jan 9, 2019 [details]
Discounted Registration Deadline: Feb 6, 2019 [details]
Click here to view Cancellation Policy
Discounted Abstract Deadline: December 11, 2018
*All deadlines end at 11:59 PM US Mountain Standard TimeAbstract Submission Fee: 100.00 USD*
Submission by this date receives 50.00 USD discount.
*50.00 USD will be applied to Registration Fee when you register
Abstract Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadlines. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract early allows us to:
- submit your abstract to organizers to be considered for a short talk
- accept your abstract online
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
(The Abstract Deadline: is January 9, 2019)
Global Health Travel Award Deadline:
*All deadlines end at 11:59 PM US Mountain Standard Time
Global Health Travel Award Details:
You MUST complete your Global Health Travel Award appplication by the Global Health Travel Award Deadline
and complete the other required steps (verify your contact information and submit a recommendation letter)
to be considered for a travel award.
Click here to learn more about Global Health Travel Awards.
Scholarship Deadline: December 11, 2018
*All deadlines end at 11:59 PM US Mountain Standard Time
Scholarship Details:
You MUST submit your abstract by the Scholarship Deadline and complete the other required steps (submit a scholarship application and submit a mentor letter) to be considered for a scholarship.
Abstract Deadline: January 9, 2019
*All deadlines end at 11:59 PM US Mountain Standard Time
Abstract Submission Fee: 100.00 USD*
*50.00 USD will be applied to Registration Fee when you register
Details: It is best to submit your abstract early. Abstract and registration spaces are limited and may fill prior to the abstract or discounted registration deadline. Submitting an abstract does not constitute or guarantee registration.
Submitting your abstract by the Abstract Deadline allows us to:
- submit your abstract to organizers to be considered for a short talk
- include your abstract on our website and in our secure mobile app
- reserve your space at the meeting for a poster presentation.**
Abstracts submitted after the Abstract Deadline will NOT be considered for a short talk.
(Discounted Abstract Deadline: is December 11, 2018)
Discounted Registration Deadline: February 6, 2019
*All deadlines end at 11:59 PM US Mountain Standard Time
Registration Fee: 845.00 USD* (includes 200.00 USD discount)
Student Registration Fee: 620.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
After the Discounted Registration Deadline:
Registration Fee: 1045.00 USD*
Student Registration Fee: 820.00 USD* (must complete student verification form)
*Includes 50.00 USD of your abstract submission fee
Registration spaces are limited and may fill prior to discounted registration deadline.
We highly recommend that you not make a reservation with these companies or any other housing service! These companies' representations to participants have been misleading. Please report any calls or correspondence you might have received to Keystone Symposia and book only through lodging links in your Keystone Symposia account, an established travel agency or directly with the hotel(s) listed on our website.
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Sunday, April 7 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, April 11 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, April 12 in order to fully experience the meeting.
SUNDAY, APRIL 7
Target Identification and Developing Antibodies for Clinical Application
Emerging Strategies for Developing Next-Generation Protein Therapeutics
Registered attendees can view abstracts starting on 03/07/2019
Targeting B Cells with Antibodies: From Oncology to Autoimmunity
Optimal Formats for Target Cell Deletion
Short Talk: Antibodies Engineered for Enhanced Binding and Effector Activity in the Low pH of the Tumor Microenvironment
Short Talk:Antibody Targeting of Carbohydrate Associated Tumor Antigens Reveals Novel Effector Cell Pathways for Tumor Clearance
Short Talk: Novel Class of NK Engagers Targeting NKp30 Selected from Unbiased Screen of Common Light Chain Based Bispecific Antibodies
A Novel CD3xPSMA Bispecific Antibody for Efficient T-Cell Mediated Killing of Prostate Tumor Cells with Minimal Cytokine Release
A Novel Cell-Based Assay for Predicting Bispecific Antibody Activity and its PK-PD Effects
A Versatile Platform for Efficient Affinity Optimization of Common Light Chain Bispecific Antibodies
Human Cytomegalovirus-Specific T Cell Receptor Engineered for High Affinity and Soluble Expression using Mammalian Cell Display
Antibodies as Drugs: P329G LALA Mutated Antibodies Enable Precise Redirection of Anti-P329G-Based Chimeric Antigen Receptor T Cells (P329G-CAR-T cells)
AT1413 T-Cell Engager Activity is Determined by T-Cell Engager Format Valency
Development of MabPair Technology, A Novel Platform for Producing Bifunctional Antibody Products
Humanization of a MUC16 Specific Monoclonal Antibody for the Treatment of Pancreatic Cancer
Engineering Non-Classical Antibody Formats Inspired by Nature
Engineering Antagonistic and Agonistic Antibodies
Engineering Antibody Specificity and Stability Using Deep Sequencing
Short Talk: Optimization of Antibody Anti Pancreatic Cancer Marker
Short Talk: Engineering the Fragment Crystallizable (Fc) Region of Antibody for Dendritic Cell-Based Vaccine
Registered attendees can view abstracts starting on 03/07/2019
Cancer Immunotherapy and Radioimmunotherapy with Bispecific Antibodies
Engineering Bispecific Antibodies for Combination Cancer Immunotherapy
Bispecific Antibodies for T Cell Recruitment and T Cell Activation
Engineering Next-Generation Chimeric Antigen Receptors
Short Talk: A Novel T-Cell Bispecific Antibody Platform for Efficient T Cell Mediated Killing of Tumor Cells with Minimal Cytokine Release
Short Talk: A T-Cell Engager Based on A Unique AML Patient-Derived Anti-CD43 Antibody Has a Strong Anti-AML Activity in vivo Without Affecting Normal Hematopoietic Cells
Short Talk: COBRA: A Novel Conditionally Active Bispecific Antibody That Regresses Established Solid Tumors in Mice
Novel Antibodies for HIV Therapy and Prevention
Antibodies for Prevention and Treatment of Viral Infections
Catching Viruses in Endosome Using Bispecific Antibodies
Short Talk: Broad and Potent Bispecific Neutralizing Antibodies against Filovirus
Short Talk: Staphylococcus Aureus Specific Monoclonal Antibodies that Escape Binding to Protein A Protect against Invasive Disease
Progress with Antibody Toxin Fusion Proteins and Overcoming Immunogenicity
The Promise of ADCs: A Simple Concept, Difficult to Execute! Where Are We Now?
Probody Therapeutics: Antibody Pro-drugs Designed for Safer and More Effective Cancer Therapies
Short Talk: Comprehensive Profiling of the Immune-Modulatory Properties of a Cytotoxic ADC Reveals Unique Contributions by the Antibody Component of the Drug
Short Talk: Antibody Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients
Short Talk: Self-Assembling and Disssembling (SADA) bispecific antibodies (BsAb) for 2-step Pretargeted RadioImmunotherapy (PRIT)
CNS Delivery of Therapeutic Proteins using a Novel Fc Fragment Blood-Brain Barrier Transport Vehicle Approach
Crossing the Blood Brain Barrier with Antibodies to Access Brain Targets
Antibody based Therapies for Neurodegenerative Diseases
Short Talk: Engineering Pharmacology Active Nanobodies to Target mGlu2 Receptor in the Brain
Short Talk: Rational Design and Systematic Optimization of Antibodies against the Aggregation of the Aβ42 Peptide
Registered attendees can view abstracts starting on 03/07/2019
A Bispecific Antibody Mimetic of FGF21 for the Treatment of Metabolic Disease and NASH
Engineering DARPins for Delivery into Cells
Bispecific CD47 Antibodies for Treatment of Cancer and Autoimmunity
Short Talk: Engineered Antibody Fragments Precisely Loaded with Diagnostic and Therapeutic Payloads with First-in-Man Biodistribution in Cancer Metastases
Short Talk: Engineering Next Generation Bispecific Antibodies Against Filoviruses
Changes in Complementarity-Determining Regions Significantly alter IgG Binding to the Neonatal Fc Receptor (FcRn) and Pharmacokinetics
Active Immunoprophylaxis Employing DNA-Encoded Monoclonal Antibodies (dMAbs™)
Dengue Virus Glycoprotein E DIII Epitope Engineering for Broadly Neutralizing Antibodies Enhancement
Development of Next-Generation Antibody Therapeutics against Cancer and Autoimmune Disease Utilizing DDS and Molecular Imaging
A Sortase A Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries
Using Monobodies to Target Cytoplasmic Oncoproteins
Registered attendees can view abstracts starting on 03/07/2019
Anti-Marco Antibodies in Tumor Immunotherapy
Optimizing Anti-Tumour Immunity through Manipulation of the Innate-Adaptive Interface using CD27 Agonists
GSK 3359609 a Non-T Cell Depleting IgG4 Anti-ICOS Antibody
Short Talk: Engineering Antibodies to Engage TRIM21 Improves Antigen Cross-Presentation in Human Monocyte-Derived Dendritic Cells
Registered attendees can view abstracts starting on 03/07/2019
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
We gratefully acknowledge the generous grant for this conference provided by:
We gratefully acknowledge additional support for this conference from:
![]() |
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |